NRAS and melanoma: While Bliss excess showed drug additivity across the entire dose–response landscape in BRAF V600E/K lines, NRAS mutant melanoma lines presented a narrow concentration range in which the combination of panRAF and MEK inhibitors was highly synergized in inhibiting cancer growth (Figure 1c).